¼¼°èÀÇ ³úô¼ö¿° ½ÃÀå º¸°í¼­(2025³â)
Encephalomyelitis Global Market Report 2025
»óǰÄÚµå : 1720792
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,183,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,938,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,692,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

³úô¼ö¿° ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¸î ³â°£ °­·ÂÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. ¿¹Ãø ±â°£ÀÇ ¼ºÀåÀº ¸é¿ª ¿ä¹ý Ä¡·áÀÇ Ã¤¿ë Áõ°¡, ÀÚ°¡ ¸é¿ª ÁúȯÀÇ À¯º´·ü Áõ°¡, °Ç°­ °ü¸® ÁöÃâ Áõ°¡, ÀÓ»ó ¿¬±¸ÀÇ È®´ë, ³úô¼ö¿°¿¡ ´ëÇÑ Àνİú ±³À° Áõ°¡¿¡ ±âÀÎÇϰí ÀÖ½À´Ï´Ù. Áúº´ ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎ¿Í ¹Î°£ ÀÚ±Ý Á¦°ø Áõ°¡µµ Áß¿äÇÑ ¿ªÇÒÀ» ÇÑ´Ù°í »ý°¢µË´Ï´Ù. ¿¹Ãø ±â°£¿¡ À־ÀÇ ÁÖ¿ä µ¿ÇâÀ¸·Î¼­´Â ¼±ÁøÀûÀÎ ¸é¿ª Á¶Àý ¿ä¹ýÀÇ °³¹ß, Á¤¹Ð »ý¹° Á¦Á¦ÀÇ Áøº¸, Á¶±â Áø´ÜÀ» À§ÇÑ ½Å±Ô ¹ÙÀÌ¿À¸¶Ä¿, ¸ÂÃãÇü Ä¡·áÀÇ ÁøÀü, Â÷¼¼´ë Ç×¹ÙÀÌ·¯½ºÁ¦ÀÇ Ã¢Ãâ, ÀÓ»ó ¿¬±¸¿¡ À־ÀÇ AIÀÇ ÅëÇÕ µîÀÌ ÀÖ½À´Ï´Ù.

ÀÚ°¡¸é¿ª ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ÇâÈÄ ¸î ³â°£ÀÇ ³úô¼ö¿° ½ÃÀåÀÇ ¼ºÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. °¨¿°Áõ,½ÄÀÌ ¿ä¹ýÀ̳ª È­ÇÐÁ¦Ç°¿¡ÀÇ ³ëÃâÀ» Æ÷ÇÔÇÑ ¶óÀÌÇÁ ½ºÅ¸ÀÏÀÇ º¯È­ µîÀÇ ¿äÀο¡ ÀÇÇÑ °÷ÀÌ Å®´Ï´Ù. À̰ÍÀº ±Ã±ØÀûÀ¸·Î ȯÀÚÀÇ QOL(»ýȰÀÇ Áú)°ú ±â´ÉÀû ÇູÀ» Çâ»ó½Ãŵ´Ï´Ù. ¿¹¸¦ µé¾î 2024³â 11¿ù µ¶ÀÏ¿¡ º»»ç¸¦ µÐ ±â°üÀÎ Versorgungsatlas.de´Â 2022³â¿¡ 7,324¸¸ 1,305¸íÀÇ º¸Çè °¡ÀÔÀÚ Áß 630¸¸ 4,340¸íÀÌ ÃÖ¼Ò ÇÑ °¡Áö ÀÌ»óÀÇ ÀÚ°¡ ¸é¿ª ÁúȯÀ» Áø´Ü¹Þ¾Æ 8.61%ÀÇ ¿ø½Ã À¯º´·üÀ» ±â·ÏÇß´Ù°í º¸°íÇß½À´Ï´Ù.

³úô¼ö¿° ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³ÇÏ´Â ±â¾÷Àº Ä¡·á È¿°ú¸¦ ³ôÀÌ°í ³úô¼ö¿°À» °ü¸®Çϱâ À§ÇÑ Ç¥Àû ¿ä¹ýÀ» °³¹ßÇϱâ À§ÇØ Ã·´Ü ´ÜÀÏŬ·ÐÇ×ü ¿ä¹ýÀÇ °³¹ß¿¡ ÁÖ·ÂÇϰí ÀÖ½À´Ï´Ù. ´ÜŬ·Ð Ç×ü´Â Áúº´¿¡ ´ëÇÑ ¸é¿ª ¹ÝÀÀÀ» µ½±â À§ÇØ Æ¯Á¤ Ç׿ø¿¡ °áÇÕÇÏ´Â ÀΰøÀûÀ¸·Î ¸¸µé¾îÁø ´Ü¹éÁúÀÔ´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 3¿ù ÀϺ» Á¦¾àȸ»çÀÎ Áß¿ÜÁ¦¾àÁÖ½Äȸ»ç´Â '´ÜÀÏŬ·ÐÇ×ü'¸¦ °³¹ßÇß½À´Ï´Ù. ÀϺ» Á¦¾àȸ»çÀÎ Áß¿ÜÁ¦¾à ÁÖ½Äȸ»ç´Â Àΰ£È­ Ç×IL-6 ¼ö¿ëü ´ÜÀÏŬ·ÐÇ×ü EnspryngÀÌ ¹Ì¿¤¸° ¿Ã¸®°í±³¼¼Æ÷ ´ç´Ü¹éÁú Ç×ü °ü·Ã Áúȯ(MOGAD)°ú ÀÚ°¡¸é¿ª¼º ³ú¿°(AIE)ÀÇ Ä¡·á·Î¼­ ÈÄ»ý³ëµ¿¼ºÀ¸·ÎºÎÅÍ ¼±±¸ ÁöÁ¤À» ¹Þ¾Ò´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ÁöÁ¤Àº Çõ½ÅÀûÀÎ Ä¡·á·Î¼­ÀÇ ¿£½ºÇöóÀ̱×ÀÇ °¡´É¼ºÀ» ÀÎÁ¤Çϰí, ÀÌ·¯ÇÑ ½Å°æÁúȯ ȯÀÚÀÇ ¾Ï¸ä ÀÇ·á ¿ä±¸¿¡ ´ëÀÀÇϱâ À§ÇÑ °³¹ß ¹× ½ÂÀÎ ½É»ç¸¦ °¡¼ÓÈ­ÇÏ°Ô µË´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ°ú Àü·«

Á¦4Àå ½ÃÀå - °Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼®°ú Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº°/±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ¿Í ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å·°ú ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, Àü·«

Á¦36Àå ºÎ·Ï

KTH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Encephalomyelitis refers to the inflammation of both the brain and spinal cord, typically caused by infections, immune system dysfunction, or other underlying medical conditions. This condition can lead to neurological problems, such as muscle weakness, paralysis, and cognitive disturbances.

The main types of encephalomyelitis include equine encephalomyelitis, associated encephalomyelitis, anti-myelin oligodendrocyte glycoprotein antibody (anti-MOG) encephalomyelitis, encephalomyelitis disseminata, acute disseminated encephalomyelitis, AIDS-related encephalomyelitis, and others. Equine encephalomyelitis is a viral disease affecting horses, caused by the eastern, western, or Venezuelan equine encephalitis viruses, leading to inflammation in the brain and spinal cord. Treatment options for encephalomyelitis include surgery, plasmapheresis, drug treatments, and other methods, and are utilized in various healthcare settings, including clinics and hospitals.

The encephalomyelitis market research report is one of a series of new reports from The Business Research Company that provides encephalomyelitis market statistics, including the encephalomyelitis industry's global market size, regional shares, competitors with a encephalomyelitis market share, detailed encephalomyelitis market segments, market trends and opportunities, and any further data you may need to thrive in the encephalomyelitis industry. This encephalomyelitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The encephalomyelitis market size has grown strongly in recent years. It will grow from $21.16 billion in 2024 to $22.65 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth during the historic period can be attributed to the increasing prevalence of autoimmune and infectious diseases, a rise in awareness regarding neurological disorders, greater investment in research and development, advancements in healthcare infrastructure, and the expanding applications of immunotherapy.

The encephalomyelitis market size is expected to see strong growth in the next few years. It will grow to $29.31 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to the increasing adoption of immunotherapy treatments, a rising prevalence of autoimmune disorders, growing healthcare expenditure, expanded clinical research, and greater awareness and education about encephalomyelitis. Additionally, the rising government and private funding for rare disease research will play a key role. Major trends in the forecast period include the development of advanced immunomodulatory therapies, advancements in precision biologics, novel biomarkers for early diagnosis, progress in personalized treatments, the creation of next-generation antivirals, the integration of AI in clinical research, and innovative gene therapy approaches.

The growing prevalence of autoimmune diseases is expected to drive the growth of the encephalomyelitis market in the coming years. Autoimmune diseases are conditions in which the body's immune system mistakenly attacks its own healthy cells and tissues. The rise in autoimmune diseases is largely attributed to factors such as genetic predisposition, environmental triggers, infections, and lifestyle changes, including diet and exposure to chemicals. Encephalomyelitis treatment helps autoimmune disease patients by reducing inflammation, managing immune system dysfunction, alleviating neurological symptoms, and preventing disease progression. This ultimately enhances their quality of life and functional well-being. For example, in November 2024, Versorgungsatlas.de, a Germany-based organization, reported that in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. Therefore, the rising incidence of autoimmune diseases is driving the growth of the encephalomyelitis market.

Companies operating in the encephalomyelitis market are focusing on the development of advanced monoclonal antibody therapies to enhance treatment efficacy and create targeted therapies for managing encephalomyelitis. Monoclonal antibodies are artificially created proteins that bind to specific antigens to assist the immune response against diseases. For instance, in March 2023, Chugai Pharmaceutical Co. Ltd., a Japan-based pharmaceutical company, announced that its humanized anti-IL-6 receptor monoclonal antibody, Enspryng, received forerunner designation from the Ministry of Health, Labor and Welfare (MHLW) for its anticipated use in treating myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and autoimmune encephalitis (AIE). This designation recognizes Enspryng's potential as an innovative treatment, accelerating its development and regulatory review to address the unmet medical needs of patients with these neurological conditions.

In January 2024, Zuellig Pharma Holdings Ltd., a Singapore-based hospital and healthcare company, partnered with Substipharm Biologics to enhance vaccine access. This partnership aims to improve the availability of the IMOJEV Japanese encephalitis vaccine across nine Asian markets, utilizing Zuellig Pharma's marketing, distribution, and ZP Therapeutics' expertise. Substipharm Biologics, a France-based pharmaceutical company, develops various vaccines, including those for encephalitis and encephalomyelitis.

Major players in the encephalomyelitis market are Merck & Co. Inc., Sanofi S.A., F. Hoffmann-La Roche Ltd., HiFiBiO Therapeutics, Zoetis Services LLC, Chugai Pharmaceutical Co. Ltd., IDEXX, Abcam Limited., EUROIMMUN Medizinische Labordiagnostika AG, Eurogentec S.A., Boehringer Ingelheim International GmbH, Creative Diagnostics, Atlas Antibodies, AnaSpec, VMRD Inc., Antibodies Incorporated, Fresenius Kabi, Hemispherx Biopharma Inc., BioStoneah, YouSeq Ltd.

North America was the largest region in the encephalomyelitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in encephalomyelitis report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the encephalomyelitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The encephalomyelitis market consists of revenues earned by entities by providing services such as chest X-rays and CT scans, rapid diagnostic tests, sputum cultures, and blood cultures. The market value includes the value of related goods sold by the service provider or included within the service offering. The encephalomyelitis market also includes sales of antiviral therapy, and corticosteroids. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Encephalomyelitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on encephalomyelitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for encephalomyelitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The encephalomyelitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Encephalomyelitis Market Characteristics

3. Encephalomyelitis Market Trends And Strategies

4. Encephalomyelitis Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Encephalomyelitis Growth Analysis And Strategic Analysis Framework

6. Encephalomyelitis Market Segmentation

7. Encephalomyelitis Market Regional And Country Analysis

8. Asia-Pacific Encephalomyelitis Market

9. China Encephalomyelitis Market

10. India Encephalomyelitis Market

11. Japan Encephalomyelitis Market

12. Australia Encephalomyelitis Market

13. Indonesia Encephalomyelitis Market

14. South Korea Encephalomyelitis Market

15. Western Europe Encephalomyelitis Market

16. UK Encephalomyelitis Market

17. Germany Encephalomyelitis Market

18. France Encephalomyelitis Market

19. Italy Encephalomyelitis Market

20. Spain Encephalomyelitis Market

21. Eastern Europe Encephalomyelitis Market

22. Russia Encephalomyelitis Market

23. North America Encephalomyelitis Market

24. USA Encephalomyelitis Market

25. Canada Encephalomyelitis Market

26. South America Encephalomyelitis Market

27. Brazil Encephalomyelitis Market

28. Middle East Encephalomyelitis Market

29. Africa Encephalomyelitis Market

30. Encephalomyelitis Market Competitive Landscape And Company Profiles

31. Encephalomyelitis Market Other Major And Innovative Companies

32. Global Encephalomyelitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Encephalomyelitis Market

34. Recent Developments In The Encephalomyelitis Market

35. Encephalomyelitis Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â